论文部分内容阅读
目的观察消癌平联合奥宁治疗卵巢癌的临床效果。方法65例晚期卵巢癌患者随机分为甲、乙两组,甲组(32例)给予消癌平联合奥宁治疗,乙组(33例)给予消癌平+化疗治疗。比较肿瘤组织生长抑素受体2(SSTR 2)和肿瘤标志物治疗前后的变化与疗效的关系。结果甲组32例,可观察的实体瘤治疗总有效率为37.5%,12例合并腹腔积液治疗总有效率为80%。乙组33例,患者的临床受益疗效(CBR)较高,SSTR 2表达与疗效比较符合率达71%(5/7),但肿瘤标志物治疗前后变化不显著。随诊结果除1例于休息阶段死亡外,其余均接受了再次治疗。结论消癌平-生长抑素类似物治疗难治性卵巢癌有确切疗效,合并应用化疗可使抗肿瘤作用获得互补。
Objective To observe the clinical effect of Xiao-Ping combined with Oinging on ovarian cancer. Methods A total of 65 patients with advanced ovarian cancer were randomly divided into two groups. Group A (32 cases) was treated with Xiaoyanping combined with Aining and group B (33 cases) with Xiaopeng + Chemotherapy. The relationship between the changes of the somatostatin receptor 2 (SSTR 2) and tumor markers before and after treatment was compared with the therapeutic effect. Results A group of 32 cases, observable solid tumors the total effective rate was 37.5%, 12 patients with ascites effusion total effective rate was 80%. In group B, 33 patients had higher clinical benefit (CBR) and 71% (5/7) coincidence rate of SSTR 2 expression and curative effect. However, the changes of tumor markers before and after treatment were not significant. Follow-up results in addition to 1 patient died during the rest, the rest were treated again. Conclusion Xiaojiaoping - somatostatin analogue treatment of refractory ovarian cancer have the exact effect of combined application of chemotherapy can make the antitumor effect of complementary.